WILLOW BIOSCIENCES ANNOUNCES ANNUAL GENERAL AND SPECIAL MEETING VOTING RESULTS

SUNNYVALE, Calif., July 26, 2024 /CNW/ - Willow Biosciences Inc. ("Willow" or the "Company") (TSX: WLLW) (OTCQB: CANSF) is pleased to announce the voting results from its annual general and special meeting of shareholders held on July 26, 2024 (the "Meeting"). A total of 27,685,611 common shares, representing approximately 21.74% of the Company's issued and outstanding shares were represented at the meeting.

The shareholders approved the setting of the number of directors of Willow at 5 directors, and the following nominees were elected as directors of Willow for the ensuing year with the specific voting results being as follows:

	Votes For		Votes Withheld
Director	#	%	#	%
Donald Archibald	19,248,325	77.19 %	5,686,936	22.81 %
Al Foreman	24,905,181	99.88 %	30,080	0.12 %
Raffi Asadorian	21,273,181	85.31 %	3,662,080	14.69 %
Dr. Jim Lalonde	24,905,317	99.88 %	29,944	0.12 %
Dr. Chris Savile	24,905,182	99.88 %	30,079	0.12 %

In addition, shareholders approved the appointment of KPMG LLP as the Company's auditor for the ensuing year (86.77% of the votes cast being in favour). The shareholders also approved the grant of unallocated share awards issuable under Willow's share award incentive plan pursuant to the requirements of the Toronto Stock Exchange. For complete voting results on all matters approved at the Meeting, please see the Company's Report of Voting Results dated July 26, 2024 available on SEDAR+ at www.sedarplus.ca.

About Willow Biosciences Inc.

Willow develops biobased processes to manufacture ingredients for the pharmaceutical, food and beverage and consumer markets. Willow's FutureGrown^TM and BioOxi^TM platforms enable large-scale production with sustainability at its core. Willow's R&D team has a proven track record of developing and commercializing bio-based manufacturing processes and products to benefit our B2B partners and their customers.

FutureGrown™ and BioOxi™ are registered trademarks of Willow Biosciences Inc.

For more information, visit www.willowbio.com

SOURCE Willow Biosciences Inc.

Travis Doupe, Chief Financial Officer, E: [email protected]